Senior Manager, Regulatory Affairs at QED Therapeutics - Palo Alto, California, US
QED Therapeutics, an affiliate company of BridgeBio Pharma, is dedicated to developing meaningful treatment options for those with achondroplasia and pursuing research to address the needs of the community. We are studying whether an investigational agent (infigratinib) has the potential to address the root cause of irregular bone growth in achondroplasia, by decreasing the overactivity of the FGFR3 receptor.